A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.

Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, Hammershaimb L, Kirkwood JM, Etaracizumab Melanoma Study Group
Cancer. 2010 116 (6): 1526-34

PMID: 20108344 · DOI:10.1002/cncr.24821

MeSH Terms (15)

Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Dacarbazine Disease-Free Survival Female Humans Integrin alphaVbeta3 Male Melanoma Middle Aged Skin Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: